SCHEMBL3857772

SCHEMBL3857772

CCN1CCC(O)(c2ccc(F)c(Cl)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 4/20 0.48
CCR1 P32246 2/20 0.47
DRD2 P14416 8/20 0.47
CCR3 P51677 1/20 0.46
DRD3 P35462 2/20 0.46
DRD4 P21917 1/20 0.46
OPRM1 P35372 2/20 0.45
OPRD1 P41143 1/20 0.44
OPRK1 P41145 1/20 0.44
SLC6A2 P23975 3/20 0.44
SLC6A4 P31645 3/20 0.44
HTR1A P08908 1/20 0.44
DRD1 P21728 1/20 0.44
DRD5 P21918 1/20 0.44
HTR2A P28223 1/20 0.44
HTR7 P34969 1/20 0.44
HRH1 P35367 1/20 0.44
HTR2B P41595 1/20 0.44
SSTR5 P35346 1/20 0.44
SLC6A3 Q01959 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3115739 0.92 KDM4E (0.44) OPRL1CCR1DRD2CCR3DRD3
SCHEMBL3851778 0.89 DRD2 (0.52) CCR1DRD2DRD3SLC6A2SLC6A4
SCHEMBL3853387 0.89 OPRL1 (0.51) OPRL1CCR1DRD2DRD3DRD4
SCHEMBL3852309 0.87 DRD2 (0.54) OPRL1CCR1DRD2DRD3DRD4
SCHEMBL3859481 0.87 DRD2 (0.48) OPRL1DRD2CCR3DRD3OPRM1
SCHEMBL3115708 0.84 DRD2 (0.50) CCR1DRD2DRD3DRD4SLC6A2
SCHEMBL10079064 0.84 CCR1 (0.50) OPRL1CCR1DRD2DRD3OPRM1
SCHEMBL3120553 0.82 DRD2 (0.51) CCR1DRD2DRD3DRD4OPRM1
SCHEMBL10287975 0.82 CCR3 (0.65) OPRL1CCR1DRD2CCR3DRD3
SCHEMBL3118837 0.81 OPRL1 (0.46) OPRL1CCR1DRD2DRD3DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070270467-A1 SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2007-11-22 US claimed
CN-101076517-A Novel substituted piperidines as modulators of dopamine neurotransmission CARLSSON A RESEARCH AB (SE) 2007-11-21 CN claimed
CN-101076517-B Substituted piperidines as modulators of dopamine neurotransmission NSAB AF NEUROSEARCH SWEDEN AB 2010-12-15 CN disclosed
US-7579474-B2 Substituted piperidines as modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH AB, SVERIGE (DK) 2009-08-25 US disclosed
US-20070270467-A1 SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2007-11-22 US disclosed
CN-101076517-A Novel substituted piperidines as modulators of dopamine neurotransmission CARLSSON A RESEARCH AB (SE) 2007-11-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270467-A1 SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION DRD2, PRLHR, DRD3 OPRL1 9/4885CCR1 2632/4885DRD2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.